Prognosis of Sepsis Sepsis
biomarker available
clinical validation of progranulin measurement
market potential
Economic advantages of progranulin
reliable biomarker
euro market
specific detection of sepsis
EU Notified Bodies
economic potential
phase
Mediagnost
day
validated test system
point of care
scientific solidity
patient care
monitoring of infection
feasibility study
clinical routine
overall objectives
multiplex test systems
complex
time delay
differentiation
Diagnostics
administrative employees
disease course
best regulatory strategy
subsequent strategic product development
inflammatory host reaction
picture
results
therapeutic costs
implementation
successful completion
direct contact
structured questionnaire
cases
cost analysis
avoidance of unnecessary antibiotic therapy
Excellent infrastructure
infectious agent
strong need
year
health challenge
mean incidence rate
Key opinion leaders
length
reimbursement requirements
intellectual property
reduction
level hospitals
literature research
work
Preliminary data
ICU